doi: 10.1016/j.immuni.2019.09.014 86
Regulatory Update 2 min read Regulator steps up surveillance as generic GLP-1 shots raise misuse concerns According to the Health Ministry, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics
Researchers modified the original peptide structure to create longer-acting formulations with various strategies: liraglutide (once daily) uses fatty acid albumin-binding, dulaglutide (once weekly) employs an Fc-fusion approach, exenatide extended-release (Bydureon, once weekly) utilises microsphere technology, and semaglutide (once weekly) incorporates fatty acid modifications
Suppression of murine lupus by CD4 + and CD8 + Treg cells induced by T cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor beta
Di Paola R, Modafferi S, Siracusa R, Cordaro M, D'Amico R, Ontario ML, Interdonato L, Salinaro AT, Fusco R, Impellizzeri D, Calabrese V, Cuzzocrea S